CA-CEPTON-TECHNOLOGIES
11.1.2021 12:02:50 CET | Business Wire | Press release
A ground-breaking lidar-based real-time crowd analytics solution has recently helped Orlando International Airport (MCO) create one of the world’s safest terminals during the COVID-19 pandemic.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210111005374/en/
Deployed by The Indoor Lab, the leading provider for monitoring real-time foot traffic using lidar sensors, the solution - called Safe Place™ - uses Cepton’s award-winning Helius™ Smart Lidar System. Helius enables The Indoor Lab to provide intelligent, anonymized, 3D tracking of people, thereby dramatically improving the usability, safety and cleanliness of large spaces. Further, The Indoor Lab’s ground-breaking visual analytics platform, leveraging the Helius Smart Lidar System, powers the Synect Evenflow Crowd Radar media lights in terminal 2 of the Orlando International Airport.
The project at Orlando International Airport is one of several early projects initiated by The Indoor Lab and Cepton as part of a strategic partnership announced today. The Indoor Lab is Cepton’s early-stage development and analytics partner shaping the future of lidar analytics. This partnership lays the foundation for long-awaited innovations that will save customers time and money, enable more efficient design of public and private commercial spaces, and add a much-needed capability to improve public safety during the COVID-19 pandemic and recovery.
Patrick Blattner, co-founder and Chief Product Officer of The Indoor Lab said: “We have a 15-year history of crowd tracking across retail, events, airports, and stadiums. So, when COVID-19 started spreading exponentially and negatively affected many public and private spaces, we consulted with leaders involved in drafting proposals for the International Franchise Association, including the use of lidar technology to help put the country back on a path towards normalcy. With public concerns focused on cleanliness of public and commercial spaces, we extended our Safe Place platform beyond occupancy and social distancing, creating the first proprietary real-time sanitization detection solution in the market. A Safe Place enabled environment ensures locations have been cleaned, distancing measures are followed, and safer occupancy levels are maintained. Our partnership with Cepton helped us deliver against this promise. Our patent-pending Safe Place platform with real-time cleaning detection is the first of its kind in the world.”
According to The Indoor Lab, the full solution implemented in Orlando led to a drastic improvement in people’s adherence to social distancing through Thanksgiving and into the busy holiday travel season. The unprecedented effectiveness of The Indoor Lab’s innovative crowd analytics solution relies on the unique, high point density and detection range of Cepton’s MMT® -based Vista® -series lidars and Cepton’s award-winning Helius system that provides object dimensions, locations and velocities at high accuracy. The mirrorless, frictionless and rotation-free MMT architecture enables lidars that are reliable and easy to integrate for both indoor and outdoor applications. In addition, Helius allows easy aggregation of data from multiple Cepton lidar sensors to form a comprehensive and extendable network for seamless tracking. For instance, this allows the anonymized tracking of the same person across large overlapping areas, which, according to The Indoor Lab, is another game-changing factor that differentiates Helius from other lidar solutions.
In the Orlando International Airport deployment, the Indoor Lab used seven Vista lidar sensors from Cepton to seamlessly cover nearly 100% of the terminal area of roughly 50,000 square feet, something that would otherwise have required significantly more video cameras, each consuming far more data and storage bandwidth compared to the lidars. Unlike video cameras, lidars also perform accurately 24/7 regardless of lighting conditions.
Another key advantage of lidar, compared to cameras, is that it does not capture biometric data. While lidar sensors provide information to help detect, track and classify objects accurately, they do not show facial features and skin/hair color, maximizing protection of people’s privacy and reducing analytical bias. “The great thing about lidar-based crowd analytics is that it is compliant with privacy laws. At the same time, the system can also integrate with point, tilt, zoom (PTZ) cameras to detect potential public safety risks, such as a bag left behind in a public space or people unexpectedly moving at high rates of speed,” explained Blattner.
The partnership between Cepton and The Indoor Lab extends beyond projects in airports. Using Cepton’s technology, The Indoor Lab is successfully monitoring real-time traffic globally across hotels, stadiums, large commercial venues and retail spaces, such as malls and stores. The Indoor Lab’s software provides state-of-the-art, real-time information on crowd density, as well as dwell times, motion tracking and speed of individuals. Using all of that data, enterprises can optimize their customers’ experience in their spaces – to manage queues, reduce crowding, optimize layout of aisles, walkways and shops, as well as address safety and security risks.
“After evaluating most of the lidar hardware and 3D perception software offerings on the market, The Indoor Lab has identified Cepton to be the leader with a combined solution that provides the point-cloud density, accuracy, reliability, and ease and cost of integration required to properly enable crowd analytics. Together with the Cepton team, we have successfully monitored and analyzed dense crowds in some of the most challenging environments,” said Patrick Mooney, co-founder and CTO at The Indoor Lab.
Dr. Jun Pei, Cepton’s co-founder and CEO, said: “We are grateful for the partnership with The Indoor Lab and for their adoption of Cepton’s cutting-edge technology to deploy their pathbreaking innovations into a range of diverse applications. The power of this partnership is already evident in the remarkable results recently showcased by The Indoor Lab with their other partners.”
“We worked closely with The Indoor Lab to ensure we were able to deliver the capabilities and accuracy needed for their smart space applications at an affordable price. Our Helius team built a ground-breaking solution that combines intelligent, powerful lidar perception with ease of integration and data efficiency. In a future where smart spaces are pivotal to positively transforming people’s experience in travel, retail, hospitality, entertainment and beyond, I’m confident that Helius will continue to set the benchmark for world-class anonymized perception needed by world-leading partners such as The Indoor Lab.”
Cepton will be showcasing its state-of-the-art lidar solutions at CES 2021 from January 11 to January 14, 2021. Please visit Cepton’s virtual booth (requires CES registration) for more information about Helius and Cepton’s full suite of lidar offerings for various markets. During CES, Cepton’s CMO Dr. T. R. Ramachandran will present at an online webinar “Lidar, What’s the Future ” on Tuesday Jan 12 at 2 p.m. (PST), hosted by North American Lighting (NAL). Additionally, Dr. Ramachandran will discuss how lidar is transforming smart cities in a virtual panel discussion “Smart City Roundtable: What is a Smart City ?” on Jan 13 at 2 p.m. (PST), also hosted by NAL. Join the sessions online to learn more about the transformational nature of lidar technology and how Cepton’s smart lidar solutions are uniquely suited for large scale deployments in smart city and smart spaces applications.
About Cepton Technologies, Inc.
Cepton provides state-of-the-art, intelligent, lidar-based solutions for a range of markets such as automotive (ADAS/AV), smart cities , smart spaces and smart industrial applications. Cepton’s patented MMT® -based lidar technology enables reliable, scalable and cost-effective solutions that deliver long range, high resolution 3D perception for smart applications.
Founded in 2016 and led by industry veterans with over two decades of collective experience across a wide range of advanced lidar and imaging technologies, Cepton is focused on the mass market commercialization of high performance, high quality lidar solutions. Cepton is headquartered in San Jose, California, USA, with a presence in Germany, Canada, Japan and India, to serve a fast-growing global customer base. For more information, visit www.cepton.com and follow us on Twitter and LinkedIn .
About The Indoor Lab
The Indoor Lab, is the leading provider for monitoring real-time foot traffic using lidar sensors. The Safe PlaceTM platform is the newest product within their portfolio of foot traffic analytic solutions and is shaping the safe return and re-opening for all businesses in the future. Beyond COVID-19, The Indoor Lab offers the most extensive combined experience in designing, developing, and deploying real-time location services for some of the most heavily trafficked retailers, monuments, airports, and stadiums worldwide. The founders were the first to introduce 3D lidar for public space tracking and have since become the market leaders delivering the most accurate privacy compliant tracking solutions in the world. For more information, visit www.theindoorlab.com and follow us on LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210111005374/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
